HCW Biologics is a biopharmaceutical company focused on discovering and developing immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. Co. has selected two molecules as its primary product candidates: HCW9218 and HCW9302. HCW9218 is designed to treat the impact of accumulated senescent cells and the Senescence-Associated Secretory Phenotype (SASP) factors which they secrete by eliminating senescent cells and reducing SASP factors. HCW9302 is designed to activate and expand regulatory T cells to suppress the activity of inflammasome-bearing cells and the inflammatory factors which they secrete. The HCWB average annual return since 2021 is shown above.
The Average Annual Return on the HCWB average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether HCWB average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the HCWB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|